144 related articles for article (PubMed ID: 3098401)
21. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
Meili EO; Dazzi H; von Felten A
Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of lyophilized cryoprecipitate in hemophilia A.
Chuansumrit A; Isarangkura P; Chantanakajornfung A; Kuhathong K; Pintadit P; Jitpraphai C; Hathirat P; Nuchprayoon C
J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S69-73. PubMed ID: 10730521
[TBL] [Abstract][Full Text] [Related]
23. Immunologic dysfunction in patients with classic hemophilia receiving lyophilized factor VIII concentrates and cryoprecipitate.
Tsoukas C; Gervais F; Fuks A; Guttmann RD; Strawczynski H; Shuster J; Gold P
Can Med Assoc J; 1983 Oct; 129(7):713-7. PubMed ID: 6225504
[TBL] [Abstract][Full Text] [Related]
24. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.
Prowse CV
Thromb Haemost; 1995 Oct; 74(4):1191-6. PubMed ID: 8560434
[TBL] [Abstract][Full Text] [Related]
25. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A.
Mauser-Bunschoten EP; Rosendaal FR; Nieuwenhuis HK; Roosendaal G; Briët E; van den Berg HM
Thromb Haemost; 1994 Jun; 71(6):703-6. PubMed ID: 7974335
[TBL] [Abstract][Full Text] [Related]
26. Dose requirement for replacement therapy in hemophilia A.
Allain JP
Thromb Haemost; 1979 Oct; 42(3):825-31. PubMed ID: 505399
[TBL] [Abstract][Full Text] [Related]
27. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
Brinkhous KM
Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
[TBL] [Abstract][Full Text] [Related]
28. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
[TBL] [Abstract][Full Text] [Related]
30. Abnormal serum transaminase levels in patients with hemophilia A.
Cederbaum AI; Blatt PM; Levine PH
Arch Intern Med; 1982 Mar; 142(3):481-4. PubMed ID: 6802093
[TBL] [Abstract][Full Text] [Related]
31. Factor VIII half-life and intensity of treatment in hemophilic patients.
Vicente V
Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932
[TBL] [Abstract][Full Text] [Related]
32. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
[TBL] [Abstract][Full Text] [Related]
33. Thawed cryoprecipitate stored for 6 h at room temperature: a potential alternative to factor VIII concentrate for continuous infusion.
Pesquera-Lepatan LM; Hernandez FG; Lim RD; Chua MN
Haemophilia; 2004 Nov; 10(6):684-8. PubMed ID: 15569162
[TBL] [Abstract][Full Text] [Related]
34. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
[TBL] [Abstract][Full Text] [Related]
35. [Suppression of factor VIII inhibitor in children with hemophilia A].
Zenz W; Muntean W
Padiatr Padol; 1987; 22(4):345-52. PubMed ID: 3125510
[TBL] [Abstract][Full Text] [Related]
36. HIV-antibody seroconversions in Dutch haemophiliacs using heat-treated and non heat-treated coagulation factor concentrates.
Wolfs TF; Breederveld C; Krone WJ; vd Hoek L; Bakker M; Smit L; Goudsmit J
Thromb Haemost; 1988 Jun; 59(3):396-9. PubMed ID: 3142077
[TBL] [Abstract][Full Text] [Related]
37. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
Guérois C; Laurian Y; Rothschild C; Parquet-Gernez A; Duclos AM; Négrier C; Vicariot M; Fimbel B; Fressinaud E; Fiks-Sigaud M
Thromb Haemost; 1995 Feb; 73(2):215-8. PubMed ID: 7792732
[TBL] [Abstract][Full Text] [Related]
38. [Perioperative management of ventricular septal defect and right coronary cusp prolapse in a patient with hemophilia A].
Nomura K; Nakamura Y; Yamagishi M; Yamamoto K; Hanada R
Kyobu Geka; 1994 Dec; 47(13):1071-4. PubMed ID: 7830356
[TBL] [Abstract][Full Text] [Related]
39. In vivo recovery of factor VIII: a comparison of one-stage and two-stage assay methods.
Nilsson IM; Kirkwood TB; Barrowcliffe TW
Thromb Haemost; 1979 Dec; 42(4):1230-9. PubMed ID: 120619
[TBL] [Abstract][Full Text] [Related]
40. Clinical application of a chromogenic substrate method for determination of factor VIII activity.
Rosén S; Andersson M; Blombäck M; Hägglund U; Larrieu MJ; Wolf M; Boyer C; Rothschild C; Nilsson IM; Sjörin E
Thromb Haemost; 1985 Dec; 54(4):818-23. PubMed ID: 3937277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
